Abstract Background After successful induction, a subset of patients with Crohn’s disease (CD) experience secondary loss response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response. The phase 3b randomised, double-blind, multicentre POWER study evaluated efficacy and safety single intravenous (IV) re-induction UST dose vs continued subcutaneous...

a diagnosis of acute pancreatitis. The patient had experienced abdominal pain, nausea, and vomiting. In the 2 months prior to admission, he had been admitted and treated for acute pancreatitis twice in another hospital. He had no history of alcohol intake or habitual drug use. The physical examination was unremarkable except for epigastric tenderness, but his amylase level was markedly raised (...

Abstract Background We studied the efficacy and safety of ustekinumab (UST) vs adalimumab (ADA) through 1 year in biologic-naïve patients (pts) with moderate-to-severe Crohn’s disease. Methods SEAVUE was a multicenter, randomized, blinded, parallel-group, active-controlled study adults CD Activity Index (CDAI) scores ?220/?450. Biologic-naïve pts failing/intolerant to conventional therapy any s...

rohn disease is a chronic inflammatory condition of the bowel characterized by periods of quiescence and inflammatory activity or “disease flares.” Although genetic factors, dysbiosis, and altered immunity are implicated in inflammatory bowel disease, the etiology is unknown.1 The peak age of onset is early in life, between 15 and 40 years, thus affecting patients during their most productive y...

Crohn's disease (CD) is a chronic inflammatory disorder associated with both mucosal and transmural inflammation of the bowel wall, involving mainly the small intestine and the colon, but possibly the entire gastrointestinal tract as well as other organs. 1 Small bowel involvement occurs in about 70% of CD patients, with up to 30% patients presenting with disease limited to the ileum. 2,3 Curre...

Abstract Background Endoscopic healing (EH) is currently the consensual long-term treatment target to achieve in Crohn’s disease (CD). However, optimization of therapy based on an endoscopic response implies a delay as endoscopy invasive procedure and cannot be used longitudinally, stressing need for non-invasive predictors EH. We aimed assess predictive role biomarkers intestinal ultrasound (I...

Behçet disease (BD) is a multisystem disease associated with a poor prognosis in cases of gastrointestinal, neurological, or vascular involvement. We conducted a multicenter, prospective, open-label, single-arm phase 3 study to determine the efficacy, safety, and pharmacokinetics of infliximab (IFX) in BD patients with these serious complications who had displayed poor response or intolerance t...

Ankylosing Spondylitis and related spondyloarthropathies form a family of rheumatic diseases that are characterized by inflammatory peripheral and axial arthritis, with predilection for sacroiliitis, and a remarkably strong association with a genetic marker, HLA-B27. The association with B27 has provided a great impetus to the epidemio-logic studies of spondyloarthropathies and also helped broa...

BACKGROUND Recurrence of Crohn's disease (CD) can occur after surgery, including end ileostomy (EI). The Rutgeerts score (RS) was developed to predict postsurgical CD recurrence via ileocolonoscopy in patients having ileocolonic resection. The role of ileoscopic evaluation via stoma for assessing recurrence of CD has not been investigated. The aim of this study was to evaluate the role of ileos...

Gravito-Soares E, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2017-223458 Description A 47-year-old woman was diagnosed with systemic lupus erythematosus (SLE) at age 27 based on articular involvement (Jaccoud’s arthropathy), lymphopaenia, thrombocytopaenia, pleuritis and positive antinuclear/anti-dsDNA antibodies. She was under azathioprine 75 mg and mycophenolate mofetil 3 g daily. Renal involv...